Introduction
China’s expanding and aging population makes the country an attractive market for manufacturers of CNS products. Key CNS drug launches to have taken place in China in recent years include: Keppra (levetiracetam) for epilepsy in 2007, Champix (varenicline) for smoking cessation in 2008 and Invega (paliperidone) for schizophrenia in 2009.
Features and benefits
* Quantify the prevalent cases of key CNS conditions in China in 2010.
* Review the current treatment of key CNS conditions in China and published treatment guidelines.
* Identify the major multinational and domestic players in the Chinese CNS market. Understand the composititon of their CNS portfolios.
* Examine the major strengths and weaknesses of the current Chinese CNS market. Understand the key opportunites and threats facing developers.
* This report is authored by an analyst and epidemiologist based in China.
Highlights
Delivery of psychiatry services in China is hindered by a shortage of qualified psychiatrists. This situation poses a key barrier to the diagnosis and treatment of psychiatric conditions in China. Follow-up services for patients suffering from mental health conditions are also weak.
The Chinese government is prioritizing mental health care and has taken steps to improve the treatment of mental health conditions in the country. The next 10 years are likely to witness a substantial increase in access to mental health services in China, thereby representing a key opportunity to players in the psychiatry sector of the CNS market.
A key threat to the uptake of CNS drugs in China is the stigma that continues to surround several CNS conditions including not only mental illnesses but neurological conditions such as Alzheimer’s disease and epilepsy. Such stigma deters patient presentation, which in turn, hinders diagnosis and treatment.
Your key questions answered
* How many prevalent cases of key CNS condititons are there in China?
* Which are the most active multinational and domestic pharmaceutical companies in the Chinese CNS market?
* How are neurology, psychiatry and pain services organized and delivered in China? What are the typical patient care pathways for key CNS conditions?
* What are the key opportunities for existing and prospective players? What are the major threats to the uptake of CNS drugs in China?
* What strategies can companies implement in order to achieve maximum penetration in the Chinese CNS market?
[Studien Infos ausblenden]
